Qalsody (tofersen)
Summary
BCBS MS has classified Qalsody (tofersen) as investigational for ALS treatment, meaning claims will be denied. The drug requires prior authorization review, and services related to administration without PA approval will be considered not medically necessary.
Get alerts when payers change rules like this one
We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.